Ongoing Advancements in Long-Acting ART: Exploring Expanding Options for HIV Prevention and Treatment

Volume 9, Issue 11

Ongoing Advancements in Long-Acting ART: Exploring Expanding Options for HIV Prevention and Treatment

In this issue:

In this issue of eHIV Review, Ethel D. Weld, MD, PhD and Michael Rose, MD from the Johns Hopkins University School of Medicine discuss the latest research advancements in long-acting antiretroviral therapy and pre-exposure prophylaxis (PrEP), exploring findings from clinical trials on twice-yearly lenacapavir for PreP, the utility of long-acting cabotegravir/rilpivirine treatment for individuals with HIV and adherence issues, and the potential of a once-weekly oral treatment regimen comprising lenacapavir and islatravir. Clinicians require greater awareness of these options, as these regimens have the potential to transform the HIV prevention and treatment landscape while addressing current barriers and expanding the availability of effective therapeutic strategies.

Learning objective:

Describe evidence and potential indications for new and emerging ART and PrEP options.

Authors:

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, MD
(she/her/hers)

Michael Rose, MD

Instructor of Medicine
Assistant Chief of Service of the Thayer Firm
Johns Hopkins University School of Medicine
Baltimore, MD

Guest Faculty Disclosures

Dr. Weld and Dr. Rose have indicated that they have no financial interests or relationships with an ineligible company. 

Unlabeled/Unapproved Uses

Dr. Weld and Dr. Rose have indicated that they will reference the unlabeled/unapproved uses of lenacapavir and longer-acting cabotegravir for PrEP, lenacapavir plus islatravir for ART, and cabotegravir/rilpivirine for people with viremia.

Program Directors:

Justin Alves, RN, FNP-BC, ACRN, CARN, CNE

Nurse Educator
Boston Medical Center
Boston, MA
(he/him/his)

Matthew Spinelli, MD, MAS

Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, CA
(he/him/his)

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, MD
(she/her/hers)

Guest Faculty Disclosures:

Dr. Weld and Dr. Rose have indicated that they have no financial interests or relationships with an ineligible company. 

Unlabeled/Unapproved Uses:

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: March 28, 2025
Expiration date: March 27, 2027

Start Issue